Stockwatch

Date	Sym	Type	Headline
2024-04-16 08:00	UU:DXR	News Release200	New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
2024-04-15 08:00	UU:DXR	News Release200	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100(TM))
2024-04-10 08:00	UU:DXR	News Release200	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
2024-04-01 08:00	UU:DXR	News Release200	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
2024-03-25 08:00	UU:DXR	News Release200	Daxor Corporation Acquires Volumex(TM) and Megatope(TM) From Its Existing Supplier Along With Glofil(TM) to Enhance Existing Suite of Diagnostics
2024-03-22 08:00	UU:DXR	News Release200	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
2024-03-18 14:18	UU:DXR	News Release200	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
2024-03-18 14:18	UU:DXR	News Release200	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
2024-03-11 08:00	UU:DXR	News Release200	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
2024-03-08 08:00	UU:DXR	News Release200	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
2024-02-26 08:00	UU:DXR	News Release200	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
2024-02-12 08:00	UU:DXR	News Release200	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
2024-02-07 08:00	UU:DXR	News Release200	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 ‚ ® Blood Volume Diagnostic Across the U.S. at Existing Accounts
2024-01-29 08:00	UU:DXR	News Release200	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
2024-01-16 08:00	UU:DXR	News Release200	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
2024-01-09 08:00	UU:DXR	News Release200	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
2024-01-02 08:30	UU:DXR	News Release200	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
2023-11-13 08:00	UU:DXR	News Release200	New Randomized Controlled Trial Demonstrates the Efficacy of Daxor ¢ € ™s BVA Guided-Care in Heart Failure Patients
2023-11-09 08:00	UU:DXR	News Release200	Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
2023-10-13 08:00	UU:DXR	News Release200	Expert Panelists Advocate Use of Daxor ¢ € ™s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
2023-10-11 08:00	UU:DXR	News Release200	New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 ‚ ® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
2023-10-04 08:00	UU:DXR	News Release200	Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
2023-09-27 08:00	UU:DXR	News Release200	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
2023-09-26 08:00	UU:DXR	News Release200	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL ¢ € ™23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR ¢ € ™S BLOOD VOLUME DIAGNOSTIC (BVA-100 ‚ ®)
2023-09-11 12:00	UU:DXR	News Release200	Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
2023-09-07 09:15	UU:DXR	News Release200	Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-28 16:15	UU:DXR	News Release200	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
2023-08-28 16:05	UU:DXR	News Release200	Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023
2023-08-10 08:00	UU:DXR	News Release200	JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100 ‚ ®
2023-07-12 08:00	UU:DXR	News Release200	JACC-HF Study Compares Daxor ¢ € ™s BVA-100 ‚ ® Volume Metric to CardioMEMS ‚ ® Pressure Metric in Heart Failure Patients
2023-07-11 08:00	UU:DXR	News Release200	Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100 ‚ ® Blood Volume Diagnostic Throughout the U.S.
2023-07-05 08:00	UU:DXR	News Release200	Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer
2023-06-22 16:15	UU:DXR	News Release200	Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering
2023-06-20 08:00	UU:DXR	News Release200	Daxor Corporation to Showcase the Benefits of BVA-100 ‚ ® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting
2023-06-15 08:00	UU:DXR	News Release200	Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
2023-06-12 08:00	UU:DXR	News Release200	Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference
2023-05-25 15:37	UU:DXR	News Release200	Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
2023-05-22 08:30	UU:DXR	News Release200	Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
2023-05-19 16:53	UU:DXR	News Release200	Daxor Corporation Announces Proposed Underwritten Public Offering
2023-05-18 08:00	UU:DXR	News Release200	New Study Demonstrates Clinical Utility of Daxor ¢ € ™s Blood Volume (BVA-100 ‚ ®) Diagnostic in Heart Failure Outcomes